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Objectives: Our understanding of a variant type of leiomyoma lags far behind of 
leiomyoma/leiomyosarcoma of the uterus. The rarity of variant type leiomyomas limits 
epidemiologic study, evidence-based guidance for diagnosis and treatment. We aimed to 
analyze clinical, pathologic and radiological features of variant type of leiomyomas in women 
who underwent surgical therapy for symptomatic disease in a tertiary center. We furthermore 
intended to put forth the recurrence patterns of variant type of leiomyoma after uterine-
conserving therapies. 
Material and methods: Pathology results and inpatient files of women undergoing surgery 
(vaginal or abdominal hysterectomy; total abdominal hysterectomy and bilateral 
salphingoopherectomy; abdominal myomectomy; polipectomy) for symptomatic disease and 
with a histologic diagnosis of variant type of leiomyoma were assessed. Patient gravida, 
parity, menopausal status, patient complaint, type of initial surgical procedure, size of 
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neoplasms, number of mitosis, presence of atypia, and necrosis, MRI evaluation, recurrence 
and any subsequent therapy were documented. 
Results: A total of 3275 patients’ medical records were evaluated between 2005–2018. The 
study sample comprised of 185 women with a diagnosis of variant type of leiomyoma. The 
patients ranged from 23 to 79 years of age. One hundred thirty-five cases were 
postmenopausal and 50 cases were during the reproductive period. The most common 
presenting symptom was menometrorrhagia (38.9%). Four point nine percent of cellular 
leiomyoma, 14.2% of smooth muscle tumors of uncertain malignant potential (STUMP) and 
4.7% of atypical leiomyomas were recurred with clinical follow-up. 
Conclusions: Clinicians should be aware of variant type leiomyomas and their associated 
clinical, imaging, and pathologic issues. 





Uterine leiomyoma and leiomyosarcoma are at opposite poles of the pathologic 
spectrum of uterine smooth muscle tumors. In between, there are variant type of leiomyomas 
including mitotically active leiomyoma, cellular leiomyoma, lipoleiomyoma, atypical 
leiomyoma, angiolipoleiomyoma and smooth muscle tumors of uncertain malignant potential 
(STUMP) [1–6]. 
Leiomyomas are benign smooth muscle tumours and are the most common solid 
tumors in women with an estimated incidence of 70% [7]. Variant type of leiomyomas were 
relatively less and it is important to differentiate them from malignant neoplasms of the 
myometrium,  since they have a good prognosis. Variant type of leiomyomas exhibit the same 
symptoms and signs as usual leiomyomas. Most variant type of leiomyomas present as typical 
fibroids and are excised if they are symptomatic. A woman with a uterine mass presumed to 
be a myoma is found to have a variant type of leiomyoma at pathologic analysis, with 
approximately 10 in 100 cases [8]. The rarity of this diagnosis limits epidemiologic study, 
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evidence-based guidance for diagnosis and treatment. Most variant types of leimyomas are 
restricted to case reports and small case series. There are no imaging modalities that can 
distinguish histologic variants from other leiomyomas. They are diagnosed by pathology 
examination following myomectomy or hysterectomy. 
Our understanding of a variant type of leiomyoma lags far behind of 
leiomyosarcoma/leiomyosarcoma of the uterus. The recurrence risk of variant type of 
leiomyoma has never been fully characterized because of the use of hysterectomy as the 
primary therapeutic option. However, the evolution of uterus preserving surgeries require 
understanding of the pathophysiology, clinical phenotype and natural history of these lesions. 
Objectıves 
Clinicians should be aware of variant typeleiomyomas and their associated clinical, 
imaging, and pathologic issues. The aim of this study was to analyze clinical, pathologic and 
radiological features of variant type of leiomyomas in women who underwent surgical 
therapy for symptomatic disease in a tertiary center. We furthermore intended to put fort the 
recurrence patterns of variant type of leiomyoma after uterine-conserving therapies. 
 
MATERIAL AND METHODS 
Medical records between 2005–2018 of Department of Obstetrics and Gynecology at 
Health Science University, Istanbul Training and Research Hospital, a tertiary center, were 
retrospectively evaluated. Pathology results and inpatient files of women undergoing surgery 
(vaginal or abdominal hysterectomy; total abdominal hysterectomy and bilateral 
salphingoopherectomy; abdominal myomectomy; polipectomy) for symptomatic disease and 
with a histologic diagnosis of variant type of leiomyoma were assessed. Patients with 
histopathological diagnosis of mitotically active leiomyoma, cellular leiomyoma, 
lipoleiomyoma, atypical leiomyoma, angiolipoleiomyoma,  vascular leiomyoma, myxoid 
leiomyoma and STUMP were included. The following data were documented: patient 
gravida, parity, menopausal status, patient complaint, type of initial surgical procedure, size of 
neoplasms, number of mitosis, presence of atypia, and necrosis, magnetic resonance imaging 
(MRI) evaluation, recurrence and any subsequent therapy. Tumor size was based on gross 
pathology. The histologic features including presence of atypical cells, overall cellularity, 
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mitotic index defined as the highest number of mitotic figures (MF) counted in 10 high-power 
fields (HPF), presence and type of necrosis were recorded. 
Dysmenorrhea, menorrhagia, menometrorrhagia, pelvic pain, pelvic mass, vaginal 
discharge, postmenopausal bleeding and prolapsus were considered to be presenting 
symptoms. Premenopausal status was defined as the occurrence of at least one menstrual 
period in the 12 months before surgery. Patients who had a concomitant gynecologic cancers 
were excluded from the study. 
 
Statistical Analysis 
IBM SPSS Statistics 22.0 program was used for statistical analysis. Descriptive 
statistical methods (mean, standard deviation) were used. Qualitative data were compared 




A total of 3275 patients’ medical records were evaluated between 2005-2018. Our 
study sample comprised of 185 women with a diagnosis of variant type of leiomyoma (102 
cellular leiomyomas, 32 lipoleiomyomas, 21 atypical leiomyomas,  8 mitotically active 
leiomyomas, 7 STUMP,  5 myxoid leiomyomas, 5 angiomyolipomas, 5 vascular 
leiomyomas).  
The surgical procedures of the cohort consisted of 110 total abdominal hysterectomies 
and bilateral salphingo-oopherectomies, 39 abdominal myomectomies, 24 total abdominal 
hysterectomies, 5 polypectomies, and 3 vaginal hysterectomies. Demographic features of 
patients were given in Table 1. The patients ranged from 23 to 79 years of age (mean age 
47.80 ± 11.29). One hundred thirty-five cases were post menopausal, 50 cases were in 
reproductive period. The most common presenting symptom was menometrorrhagia (n: 72, 
38.9%), followed by pelvic pain (n: 44, 23.8%). 
Distribution of tumor characteristics were given in Table 2. The size of the variant 
type of leiomyoma ranged from 2 cm to 26 cm, with a median of 8 cm. By the highest count 
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method, 140 cases were found to have 0 MF/10HPF, 23 showed 1 to 3 MF/10HPF, and 22 
cases were found to have ≥ 3 MF/10HPF. While 29 (15.7%) of the cases had atypia, 156 
(84.3%) had no atypia. The necrosis was observed in 9 (4.9%) of the cases and not observed 
in 176 (95.1%). One hundred seventy-nine (96.75%) of tumors affected the uterine corpus, 
and 6 (3.25%) was in the cervix uteri. 
Thirty-six of the patients had MRI evaluations. Eighty-three point three percent of 
cases showed hypointensity on T1 weighted images, 75% of cases showed hyperintensity on 
T2 weighted images, 66.7% of the cases had positive fat substraction and all of the 36 cases 
showed contrast enhancement. 
None of mitotically active leiomyomas, lipoleiomyoma, myxoid leiomyomas, 
angiomyolipomas and vascular leiomyomas were recurred; however, 5 of 102 (4.9%) cellular 
leiomyomas and one of 21 (4.7%) atypical leiomyoma were recurred during clinical follow-
up. 
Evaluation of clinical parameters according to pathologic diagnosis were given in 
Table 3. There was a statistically significant difference between the number of gravida and 
parity according to diagnosis (p < 0.01). The incidence of myxoid leiomyoma and STUMP 
were higher in cases with gravida and parity number  ≥ 5. Angiolipoleiomyoma was not 
observed in patients with gravida number ≥ 5. Angiolipoleiomyoma, mitotically active 
leiomyoma and vascular leiomyoma were not observed in patients with parity number ≥5. 
There was a statistically significant difference between tumor diameters according to 
diagnosis (p < 0.01). The incidence of myxoid leiomyoma, STUMP and vascular leiomyoma 
were higher in patients with tumor diameter of ≥ 10 cm. Angiolipoleiomyoma and mitotically 
active leiomyoma were not observed in those patients. 
There was a statistically significant difference between menometrorrhagia symptom 
according to diagnosis (p < 0.01). The incidence of angiolipoleiomyoma was higher in 
patients with menometrorrhagia than other diagnoses. Myxoid leiomyoma and STUMP 
diagnoses were not observed in those patients. 
There was a statistically significant difference between the number of mitosis 
according to diagnosis (p < 0.01). The incidence of mitotically active leiomyoma and STUMP 
were higher in cases with mitosis number ≥ 3. Angiolipoleiomyoma, lipoleiomyoma, myxoid 
leiomyoma and vascular leiomyoma were not observed in those patients. 
There was a statistically significant difference between the presence of atypia 
according to diagnosis (p < 0.01). The incidence of atypical leiomyoma and STUMP were 
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higher in patients with atypia. Angiolipoleiomyoma, lipoleiomyoma, myxoid leiomyoma and 
vascular leiomyoma were not observed in those patients. 
There was a statistically significant difference between the presence of necrosis 
according to the diagnosis (p < 0.01). The incidence of STUMP was higher in patients with 
necrosis compared to other diagnoses. Angiolipoleiomyoma, lipoleiomyoma, myxoid 
leiomyoma and vascular leiomyoma were not observed in those patients. 
 
DISCUSSION 
In the present study, we aimed to reveal our 13 year clinical experince of variant type 
of leiomyomas. Since variant type of leiomyomas have a greater risk for recurrence than 
benign leiomyomas, careful analysis of clinical and pathological features will help treatment 
planning and follow-up strategies.  
Variant type of leiomyomas were relatively less, but it is important to differentiate 
them from malignant neoplasms of the myometrium,  as they have good prognosis. Tumor 
size, presence or absence of necrosis, cytological atypia and vascular invasion, nature of 
tumor margins are most important histological features for differentiation. Variant type of 
leiomyomas include mitotically active leiomyoma, cellular leiomyoma, lipoleiomyoma, 
atypical leiomyoma, angiolipoleiomyoma,  vascular leiomyoma, myxoid leiomyoma and 
smooth muscle tumors of uncertain malignant potential (STUMP) [1–6].  
Cellular leiomyoma constitues 5% of leiomyomas. The clinical data on cellular 
leiomyoma are scanty. The recurrence rate after myomectomy is 8–12% for patients 
underwent myomectomy [9, 10]. They have increased cellularity compared to the adjacent 
myometrium [7, 11,12]. The disease is often considered benign but should not be considered 
as having a completely benign course. Hysterectomy is an option for patients who do not wish 
to preserve their fertility. Women who wish to retain fertility deserve a close follow-up. Close 
follow-up is also recommended even if total hysterectomy has been performed because 
disease recurrence, metastases and malignant transformations can occur even after 10 years 
[13, 14]. In our study, 55.1% of variant type of leiomyoma cases were cellular leiomyoma. 
Four point eighty-eight percent of cellular leiomyomas originated from cervix uteri. The rest 
of the cases originated from corpus uteri. One of the cases diagnosed as cellular leiomyoma 
after myomectomy procedure was presented with a mass two years later and hysterectomy 
was performed. The pathological diagnosis was leiomyoma. Another mass at the pelvis with a 
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diameter of 4 cm was detected at the same patient two years following second operation. The 
pathological result of pelvic mass was cellular leiomyoma. 
Two cases with cellular leiomyoma diagnosis were presented with mass three and 
eight years following first operations (myomectomy). Pathological examination of the 
materials were leiomyoma and adenomyosis. One other case with cellular leiomyoma 
recurred from the cervix uteri with a diameter of 6 cm five years after myomectomy, was 
hysterectomized and pathology was cellular leiomyoma.   
One of the cases had polipectomy. The histology was variant type of leiomyoma 
(cellular leiomyoma). Two years following first operation, the patient had another 
polipectomy procedure. The pathologic result was adenosarcoma with 3 cm diameter. 
Surgical staging was performed and the follow-ups were unremarkable. 
Lipoleiomyomas are uncommon and their reported incidence constitutes 0.03 to 0.2% 
of benign uterine tumors [15, 16, 17]. Since most cases are not involved due to their benign 
behaviour and they show histological features of admixture of varying amounts of mature 
adipose tissue with smooth muscle cells, their exact incidence is unknown. These tumors 
usually occur in postmenopausal women between 50–75 years of age [17]. Cytological atypia, 
necrosis, and calcification were not seen. The mitotic rate was zero in all cases. In our study; 
the incidence was 17.3%. Lipoleiomyomas sometimes are accompanied by anomalous blood 
vessels surrounded by smooth muscle cells and called angiomyolipoma [17]. In our case the 
2.7%  of the variant type of leiomyomas was angiomyolipoma. None of the lipoleiomyoma 
and angiomyolipoma cases were recurred. 
Myxoid leiomyoma is consist of benign smooth muscle cells with myxoid material 
separating the tumor cells. The margins are circumscribed and neither cytological atypia nor 
mitotic figures are present. [18–20]. In our cohort; 2.7%  of the variant type of leiomyomas 
was myxoid leiomyoma. None of them were recurred.  
Mitotically active leiomyoma is defined as tumours having 5–15 mitoses/10 HPFs but 
lacking necrosis or cytological atypia. The clinical behaviour is like that of a benign neoplasm 
and may be seen in patients with pregnancy or taking exogenous hormones [11, 21]. In our 
cohort; 4.3%  of the variant type leiomyomas was mitotically active leiomyoma and none of 
them was recurred. 
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Atypical leiomyoma shows the presence of atypical cells and demonstrates moderate-
severe cytologic atypia [11]. They resemble leiomyosarcomas. Most noticeable marker is low 
mitotic activity and absence of necrosis [5]. Twenty-one (11.4%) cases in our study, showed 
only nuclear atypia without necrosis or significant mitoses and hence were diagnosed as 
atypical leiomyoma. Five out of seven recurrent cases were cellular leiomyoma.  Only one of 
the seven recurrent cases was atypical leiomyoma. The first operation was myomectomy and 
recurred after seven years. Myomectomy was performed again due to fertility preservation 
demand of the patient. The pathological result of second specimen was atypical leiomyoma.    
Uterine smooth muscle tumor of uncertain malignant potential (STUMP) is a rare 
diagnosis. It is defined by the World Health Organization (WHO) as a smooth muscle tumor 
between benign and malignant criteria [5]. It is mostly seen in patients  in their forties, who 
were operated with a leiomyoma diagnosis. Risk factors and prognosis are not exactly known, 
but there is risk of recurrence or metastasis in long term follow-up. The following histologic 
findings including a smooth muscle tumor with an uncertain type of necrosis, the presence of 
focal or diffuse cytologic atypia but the mitotic count is < 10/10 HPF, the presence of 
coagulative tumor necrosis but mitosis is < 10/10 HPF, and cellular tumors with > 15 
mitosis/10 HPF are frequently encountered [22]. A retrospective study of Dańska-Bidzińska 
et al., evaluated the clinical and pathological features and outcomes of ten patients diagnosed 
with STUMP. Uterine bleeding was the second most frequent symptom. They performed 
conservative procedure in three cases, whereas in other patients hysterectomy was performed. 
Diameter of the tumors ranged from 3 to 29 cm. In all tumors mitoses were less than 10 per 
10/hpf, atypia of middle or severe type, and in three cases necrosis was observed. They 
revealed no recurrence during the follow-up period [23]. In our study; 7 (3.8%)  of the variant 
type of leiomyomas was STUMP. Diameter of the tumors were > 10 cm in all cases. They all 
showed mitosis < 10/10 HPF, atypia and necrosis. Hysterectomy was performed in all seven 
patients. One of them (14.2%) was recurred. 
The exact diagnosis of a variant type of leiomyoma made with pathologic 
examination. But hypointense T1 signal intensity, moderate T2 signal intensity, hyperintensity 
on Diffusion-weighted imaging (DWI),  if present, might raise the possibility of a leiomyoma 
variant [24]. In our sample, 36 of the patients had MRI evaluations. Eighty-three point three 
percent of cases showed hypointensity on T1 weighted image, 75% of cases showed 
hyperintensity on T2 weighted image, 66.7% of the cases had positive fat substraction and all 
of the 36 cases showed contrast enhancement. 
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In our study; 4.9 % of cellular leiomyoma, 14.2% of STUMP and 4.7% of atypical 
leiomyomas were recurred with clinical follow-up. In the literature; Zhang et al., [25] reported 
that none of six mitotically active leiomyomas and none of 17 cellular leiomyomas were 
recurred. Three out of 31 atypical leiomyomas and three of 14 STUMP with clinical follow-
up were recurred. Kim et al., [26] reported an isolated case of a mitotically active leiomyoma 
recurrence as a leiomyosarcoma. Taran et al., [13] reported two out of 99 patients with 
cellular leiomyomas (2%) had recurrent disease. Studies in the literature suggest that atypical 
leiomyomas and uterine STUMPs may have a greater risk of recurrence [27–29]. 
 
CONCLUSIONS  
Clinicians should be aware of variant type leiomyomas and their associated clinical, 
imaging, and pathologic issues. Understanding the diversity of variant type of leiomyoma in 
both pathology and symptomatology will lead to targeted therapy in the short term and 
prevention strategies in the long term in clinical practice. Since most variant type of 
leiomyomas mimic malignancy in one or more respects, diagnosis should be done by 
experienced pathologists due to the fact that they might be misdiagnosed. Though the 
frequency with which they occur remains less, their correct diagnosis was essential for a 
conservative management in patients wishing to preserve fertility.  
Also, as we reveal, there is increasing evidence that variant type of leiomyomas may 
have recurrence potential. In clinical practice, the importance of exhaustive histopathological 
examination should be emphasized once again. Confirmed diagnosis is mandatory and has 
paramount importance for optimal management, and surveillance of the concerned patients. 
We emphasize on imperative submission of all hysterectomy specimens for histopathology, 
thorough sampling, and diligent quest for associated pathologies in routine hysterectomy 
specimens, few of which may need further management and surveillance for the patient’s 
well-being. Early identification of these lesions may be beneficial for adequate treatment and 
follow-up. Prospective studies with longer follow-up would be important to gain insight into 
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Table 1. Demographic features of patients 
  n % 
Gravida <5 120 64.9 
 ≥ 5 65 35.1 
Parity < 5 163 88.1 
 ≥ 5 22 11.9 
Menopausal status Premenopause 135 73 
 Postmenopause 50 27 
Presenting symptom Vaginal discharge 2 1.1 
 Menorrhagia 21 11.3 





 Pelvic pain 44 23.8 
 Pelvic pain and mass 1 0.5 
 Pelvik pain and prolapsus 3 1.6 
 Postmenopausal bleeding 19 10.3 
Operation         TAH + BSO 110 59.5 
         TAH 24 13 
         Myomectomy 39 23.2 
         Polipectomy 5 2.7 
         VAH 3 1.6 
Diagnosis          Angiolipoleiomyom 5 2.7 
          Atypical leiomyom 21 11.4 
          Lipoleiomyom 32 17.3 
          Myxoid leiomyom 5 2.7 
          Mitotically active 8 4.3 
          Cellular leiomyom 102 55.1 
          STUMP 7 3.8 
          Vascular leiomyom 5 2.7 
14 
 
n — Number; TAH — Total abdominal hysterectomy; BSO — Bilateral 
salphingoopherectomy; STUMP – smooth muscle tumors of uncertain malignant potential 
 
Tablo 2. Distribution of tumor characteristics 
  
Min–Max 
Mean ± SD 
(median) 
Tumor diameter (cm)  2–26 8.55 ± 5.21 (8) 
  N % 
Number of mitosis 0 140 75.7 
 1 15 8.1 
 2 8 4.3 
 ≥ 3 22 11.9 
Atypia – 156 84.3 
 + 29 15.7 
Necrosis – 176 95.1 
 + 9 4.9 
T1 (n = 36) Isointense 6 16.7 
 Hypointense 30 83.3 
T2 (n = 36) Isointense 1 2.8 
 Hypointense 8 22.2 
 Hyperintense 27 75 
Fat substraction (n = 36) – 24 66.7 
 + 12 33.3 
Contrast enhancement (n = 
36) 
+ 36 100 












































n; % n; % n; % n; % n; % n; % n; % n; % 
**Gravida ≥ 5 0; 0 8; 38.1 
14; 
43.8 
5; 100 3; 37.5 
26; 
25.5 
7; 100 2; 40 
**Parity ≥ 5 0; 0 1; 4.8 5; 15.6 5; 100 0; 0 4; 3.9 7; 100 0; 0 
**Tumor 
Diameter ≥ 10 
0; 0 2; 9.5 6; 18.8 5; 100 0; 0 
22; 
21.6 
7; 100 3; 60 
**Menometror
rhagia 
5; 100 7; 33.3 
10; 
31.3 
0; 0 6; 75 
42; 
41.2 
0; 0 2; 40 





5; 100 5; 62.5 
56; 
54.9 
7; 100 4; 80 
TAH 0; 0 2; 9.5 3; 9.4 0; 0 2; 25 
16; 
15.7 
0; 0 1; 20 
Myomectomy 5; 100 7; 33.3 4; 12.5 0; 0 1; 12.5 
26; 
25.5 
0; 0 0; 0 
Polipectomy 0; 0 0; 0 2; 6.3 0; 0 0; 0 3; 2.9 0; 0 0; 0 
VAH 0; 0 1; 4.8 1; 3.1 0; 0 0; 0 1; 1 0; 0 0; 0 
**Mitosis ≥ 3 0; 0 2; 9.5 0; 0 0; 0 5; 62.5 8; 7.8 7; 100 0; 0 
**Atypia 0; 0 
16; 
76.2 
0; 0 0; 0 0; 0 6; 5.9 7; 100 0; 0 
**Necrosis 0; 0 1; 4.8 0; 0 0; 0 0; 0 1; 1 7; 100 0; 0 
Ki — Kare test was used  **p < 0.01 
n — Number; TAH — Total abdominal hysterectomy; BSO — Bilateral 
salphingoopherectomy; VAH — Vaginal hysterctomy; STUMP — smooth muscle tumors of 
uncertain malignant potential 
